European experience of docetaxel and cisplatin in advanced gastric cancer
| Autor: | Arnaud D. Roth |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Paclitaxel medicine.medical_treatment Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use Phases of clinical research Docetaxel Disease-Free Survival Stomach Neoplasms Surgical oncology Internal medicine Stomach Neoplasms/drug therapy/pathology Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged ddc:616 Cisplatin ddc:617 business.industry Gastroenterology Cancer Paclitaxel/administration & dosage/analogs & derivatives General Medicine Middle Aged medicine.disease Regimen Fluorouracil/administration & dosage Toxicity Disease Progression Female Taxoids Fluorouracil business Adjuvant Cisplatin/administration & dosage medicine.drug |
| Zdroj: | Gastric Cancer, Vol. 5 Suppl 1 (2002) pp. 27-9 |
| ISSN: | 1436-3305 1436-3291 |
| DOI: | 10.1007/s10120-002-0204-5 |
| Popis: | The combination of docetaxel with cisplatin in gastric cancer is a promising development. In a phase II study, 85-100 mg/m2 docetaxel plus 75 mg/m2 cisplatin was established as an active regimen in advanced gastric cancer (with an overall response rate of 56%) with a manageable safety profile. Up to 300 mg/m2 5-fluorouracil (5-FU) given by continuous infusion for 2 of 3 weeks can be added to this regimen without an increase in appreciable toxicity. The efficacy of docetaxel-based regimens remains to be established by a randomized phase III study. However, the results of such trials are eagerly awaited, as are data from studies of docetaxel-based combinations in the adjuvant and neoadjuvant settings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink